Company Overview and News

 
Ericsson row: RCom says relief from TDSAT, can proceed with spectrum sale without bank guarantee

2018-10-03 livemint
New Delhi: Reliance Communications on Wednesday said it has got relief from the telecom tribunal and will now be able to complete its planned spectrum sale, whose proceeds will be used to make payments to Ericsson India and RITL minority investors.
532662 RCOM HTMEDIA 532712

 
Reliance Entertainment denies financing Julie Gayet film

2018-09-26 livemint
New Delhi: Reliance Entertainment, a part of the Anil Dhirubhai Ambani Group, on Wednesday dismissed as “baseless allegations” news reports that said that the company had signed a pact to finance a film by French actress-producer Julie Gayet, partner of former French president Francois Hollande.
532662 HTMEDIA

 
HT Media Limited - Shareholders meeting

2018-09-26 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
532662 HTMEDIA

 
HT Media Limited - Shareholders meeting

2018-09-26 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
532662 HTMEDIA

 
RCom caps borrowing limit to ₹50,000 crore

2018-09-19 livemint
New Delhi: Debt-ridden Reliance Communications said on Wednesday its shareholders have approved a cap of ₹50,000 crore on its borrowing limit.
532662 HTMEDIA

 
RCom awaiting final govt approval for spectrum sharing and trading: Anil Ambani

2018-09-19 livemint
Mumbai: Reliance Communications Ltd (RCom) is awaiting final approvals for spectrum sharing and trading from the department of telecommunications (DoT) to sell its assets, chairman Anil Ambani told shareholders at the company’s annual general meeting on Tuesday. Speaking to shareholders, Ambani said that RCom’s other monetization measures, including the sale of telecom infrastructure and fibre to Reliance Jio Infocomm Ltd, were at an advanced stage.
YESBANK DB HTMEDIA 532505 532648 YYBKY 532712 CRARF 532662 PNJZY RCOM 532461 ACA PNB CRARY UCOBANK SBAZ

 
GIC, Abu Dhabi Investment, Canada’s pension board in race to pick 25% stake in Reliance Home Finance

2018-09-10 livemint
New Delhi: Abu Dhabi Investment Authority, Singapore’s sovereign wealth fund GIC and Public Sector Pension Investment Board of Canada are in race to pick 25% stake in Reliance Home Finance for ₹1,500-2,000 crore, sources said.
532662 RELCAPITAL HTMEDIA 500111

 
IDBI Bank moves NCLT against Reliance Naval’s ₹1,250 crore loan default

2018-09-06 livemint
Mumbai: IDBI Bank Ltd has approached the dedicated bankruptcy court against Reliance Naval and Engineering Ltd for defaulting on loans totaling more than ₹1,250 crore.
500390 RELINFRA 532662 500116 RELEY RIFS IDBI HTMEDIA RIFA RELFF

 
HT Media Limited - Updates

2018-08-29 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
532662 HTMEDIA

 
HT Media Limited - Updates

2018-08-29 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
532662 HTMEDIA

 
RInfra defaults on Rs 133 cr NCD redemption payment

2018-08-23 livemint
New Delhi: Reliance Infrastructure (RInfra) has defaulted on payment of redemption of non convertible debentures (NCDs) amounting to Rs 133.38 crore. The company said it expects to make these payments in the next few days from the proceeds from the sale of Mumbai power business to Adani Transmission for Rs 18,800 crore.
500390 RELINFRA 532662 RELEY RIFS 539254 HTMEDIA RIFA RELFF ADANITRANS

 
RCom sells assets worth Rs 2,000 crore to Reliance Jio

2018-08-23 livemint
Bengaluru: Reliance Communications Ltd said on Thursday that it has completed the sale of its media convergence nodes (MCNs) and related infrastructure assets worth Rs 2,000 crore to Reliance Jio Infocomm Ltd, a unit of Mukesh Ambani-owned Reliance Industries Ltd.
532662 RCOM HTMEDIA 532712

 
Crunch time comes for RCom debt restructuring

2018-08-21 livemint
Hong Kong: Reliance Communications Ltd, the Indian mobile operator that defaulted on its dollar bonds last year, is up against the clock. The company controlled by billionaire Anil Ambani is in the midst of restructuring the $300 million US currency notes and plans to meet those bondholders on 24 August to seek approval on extraordinary resolutions. Those talks come ahead of a 27 August deadline set by the Reserve bank of India for firms with delinquent accounts and under other conditions to implement resolution plans with local lenders to stave off insolvency proceedings.
532662 RCOM HTMEDIA 532712

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...